Article

Roche cervical cancer - screening, triage and diagnosis

The Roche Cervical Cancer Portfolio supports clinical decision-making across the continuum of screening, triage and diagnosis.

The Roche Cervical Cancer Portfolio provides three clinically validated tests to help identify women at risk of cervical cancer and improve detection and confirmation of high-grade disease in a single round of screening. Our portfolio of proven molecular and tissue-based tests utilizes the science of HPV and biomarker technology to deliver highly sensitive and specific results, helping bring more clarity of answers for clinical decisions.

We understand how important it is for laboratory professionals to support healthcare providers and patients with accurate results. As the HPV-vaccinated population continues to grow, the positive predictive value of finding a lesion on Pap cytology decreases and traditional methods of detection become less effective. To combat this challenge, labs need the automation, throughput, and quality control found in our products to confidently handle primary screening volume and protect women from developing cervical cancer. The science, clinical proof, and biomarker technology behind our portfolio delivers simplicity, safety, and efficiency currently missing from older testing options.

Know now if she is at risk for cervical cancer

Screening with HPV DNA can identify women at risk for cervical cancer. The cobas^® HPV test is the first clinically validated, FDA-approved, CE-IVD marked HPV DNA test for all cervical screening indications: primary screening, ASC-US triage and co-testing. cobas^® HPV simultaneously provides pooled results on known high-risk HPV genotypes and individual results on the two highest-risk genotypes, HPV 16 and HPV 18, giving three results in one from a single sample.

Know now if she is progressing toward cervical cancer

Based on biomarker technology, CINtec^® PLUS Cytology can help determine whether cells are undergoing oncogenic transformation. CINtec^® PLUS Cytology dual-stain simultaneously detects p16 and Ki-67; it is abnormal for these two biomarkers to be expressed together in a single cell. A positive dual stain result indicates an increased risk for cervical disease caused by an HPV infection.

Know now if she has cervical precancer

Diagnose with CINtec^® Histology, the only clinically validated test that uses advanced p16 biomarker technology to confirm the presence of cervical lesions due to transforming HPV infection. CINtec^® Histology enhances the identification of occult cervical lesions that may be missed by H&E or morphological interpretation alone and is useful in evaluation of differential diagnostic cases.

Explore cervical cancer products

Product portfolio

Sample Collection for Cervical Cancer Screening programs

Roche Cell Collection Medium provides stability for specimens for preservation and transport, supporting the entire cervical cancer screening workflow.

View now

Explore